Healthcare Decliners: Arrowhead Research (NASDAQ:ARWR), Prothena Corporation PLC (NASDAQ:PRTA), Heron Therapeutics (NASDAQ:HRTX), ImmunoGen (NASDAQ:IMGN), Intercept Pharmaceuticals (NASDAQ:ICPT)

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -10.47%. On last trading day company shares ended up $13.42. Analysts mean target price for the company is $27.90. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average is 8.04%.

Prothena Corporation PLC (NASDAQ:PRTA), a clinical stage biotechnology company, said it has priced an underwritten public offering of 4.75 million of its ordinary shares at $22.50 per ordinary share, before underwriting discounts and commissions. All the ordinary shares in the offering are to be sold by Prothena. Further, the underwriters were granted a 30-day option to buy up to an additional 712,500 ordinary shares. Prothena Corporation PLC (NASDAQ:PRTA) shares fell -5.28% in last trading session and ended the day on $21.89. PRTA its return on assets is -9.30%. Prothena Corporation PLC (NASDAQ:PRTA) quarterly performance is -45.37%.

Heron Therapeutics Inc (NASDAQ:HRTX), a specialty pharmaceutical company, announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration. All of the shares in the proposed offering are to be sold by Heron Therapeutics, Inc.Heron Therapeutics Inc (NASDAQ:HRTX) shares moved down -8.85% in last trading session and was closed at $11.64, while trading in range of $11.30-$11.79. Heron Therapeutics Inc (NASDAQ:HRTX) year to date performance is 29.33%.

UBS upgraded Immunogen Inc. (NASDAQ: IMGN) from Sell to Neutral with a price target of $13 (from $8.50).ImmunoGen, Inc. (NASDAQ:IMGN) ended the last trading day at $12.04. Company weekly volatility is calculated as 4.56% and price to cash ratio as 6.30. ImmunoGen, Inc. (NASDAQ:IMGN) showed a negative weekly performance of -8.44%.

Intercept Pharmaceuticals (NASDAQ:ICPT) CMO David Shapiro unloaded 4,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $278.15, for a total value of $1,112,600.00. Following the completion of the transaction, the chief marketing officer now directly owns 14,440 shares in the company, valued at approximately $4,016,486. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) weekly performance is -11.00%. On last trading day company shares ended up $253.65. Analysts mean target price for the company is $558.33. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) distance from 50-day simple moving average is -1.79%.